DE69535713D1 - Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette - Google Patents

Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Info

Publication number
DE69535713D1
DE69535713D1 DE69535713T DE69535713T DE69535713D1 DE 69535713 D1 DE69535713 D1 DE 69535713D1 DE 69535713 T DE69535713 T DE 69535713T DE 69535713 T DE69535713 T DE 69535713T DE 69535713 D1 DE69535713 D1 DE 69535713D1
Authority
DE
Germany
Prior art keywords
gamma chain
receptor
cell
interleukin
common
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69535713T
Other languages
English (en)
Other versions
DE69535713T2 (de
Inventor
Vassiliki A Boussiotis
Lee M Nadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of DE69535713D1 publication Critical patent/DE69535713D1/de
Application granted granted Critical
Publication of DE69535713T2 publication Critical patent/DE69535713T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
DE69535713T 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette Expired - Fee Related DE69535713T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US270152 1994-07-01
US08/270,152 US6576236B1 (en) 1994-07-01 1994-07-01 Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
PCT/US1995/008320 WO1996001122A1 (en) 1994-07-01 1995-06-30 Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain

Publications (2)

Publication Number Publication Date
DE69535713D1 true DE69535713D1 (de) 2008-04-03
DE69535713T2 DE69535713T2 (de) 2009-03-19

Family

ID=23030131

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535713T Expired - Fee Related DE69535713T2 (de) 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Country Status (10)

Country Link
US (2) US6576236B1 (de)
EP (2) EP0768890B1 (de)
JP (2) JPH10502372A (de)
AT (1) ATE386537T1 (de)
AU (1) AU2915295A (de)
CA (1) CA2194239A1 (de)
DE (1) DE69535713T2 (de)
DK (1) DK0768890T3 (de)
ES (1) ES2299174T3 (de)
WO (1) WO1996001122A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362192B2 (ja) * 1994-12-06 2003-01-07 味の素株式会社 検査方法及び検査薬
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
ATE292689T1 (de) * 1995-05-04 2005-04-15 Us Navy Verbesserte verfahren zur transfektion der t- zellen
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0773313B1 (de) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
ATE476496T1 (de) * 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
WO1998034631A1 (en) * 1997-02-07 1998-08-13 Thomas Jefferson University Peptide mimetics of the cytokine receptor gamma chain
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US20020031787A1 (en) * 2000-02-04 2002-03-14 Maclaren Noel K. Compositions and methods for reducing autoimmunity
CA2442066C (en) * 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
ES2297461T3 (es) 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
EP1987065A4 (de) * 2006-02-16 2010-01-20 Nascent Biolog Inc Verfahren zur verbesserung der immunfunktion und verfahren zur verhinderung oder behandlung von krankheiten bei säugetieren
US20110112196A1 (en) 2007-02-08 2011-05-12 Matvey E Lukashev Nrf2 screening assays and related methods and compositions
JP2016523102A (ja) * 2013-06-24 2016-08-08 アントフロゲネシス コーポレーション Ｔ細胞を増殖させるための方法
EP3917962A1 (de) 2019-02-01 2021-12-08 Regeneron Pharmaceuticals, Inc. Anti-il2 -rezeptor-gamma antigen-bindende proteine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (de) 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2003455C (en) 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
KR920700698A (ko) * 1989-07-25 1992-08-10 존 에프. 듀엔테 아메리카 자리콩 항바이러스성 단백질-모노클로날항체 결합체
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
DE69123361T2 (de) * 1990-09-06 1997-04-30 Schering Corp Verwendung von interleukin-4 zur behandlung der festen tumoren
EP0564531B1 (de) 1990-12-03 1998-03-25 Genentech, Inc. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
EP0580737B1 (de) 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
DE69333969T2 (de) 1992-10-30 2006-09-14 The General Hospital Corp., Boston Wechselwirkendes Fallensystem zur Isolierung von Proteinen
EP0621338A3 (de) * 1993-04-21 1997-10-29 Ajinomoto Kk Die Interleukin-2 Antwort blockierende Immunsuppressor.
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain

Also Published As

Publication number Publication date
ES2299174T3 (es) 2008-05-16
EP0768890B1 (de) 2008-02-20
US6576236B1 (en) 2003-06-10
DK0768890T3 (da) 2008-06-09
US20040037808A1 (en) 2004-02-26
AU2915295A (en) 1996-01-25
EP0768890A1 (de) 1997-04-23
CA2194239A1 (en) 1996-01-18
JP2007112815A (ja) 2007-05-10
ATE386537T1 (de) 2008-03-15
WO1996001122A1 (en) 1996-01-18
JPH10502372A (ja) 1998-03-03
EP1958966A2 (de) 2008-08-20
DE69535713T2 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
DE69535713D1 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
DE69330227D1 (de) Zur ortsspezifischen rekomination fähige agrobakterium stämme
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
ATE47866T1 (de) Copolymere auf basis von maleinsaeureanhydrid und alpha, beta-ungesaettigten verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als paraffininhibitoren.
DE3675632D1 (de) Verfahren zur einbringung von sauerstoff in wasser und vorrichtung zur durchfuehrung des verfahrens.
DE3671640D1 (de) Kationische emulsionen von bitumen-polymerartigen bituminoesen bindemitteln und kationisches emulgiersystem, unter anderem verwendbar zur erhaltung derselben.
DE3583189D1 (de) Carbazole und ihre verwendung als photoinitiatoren von photopolymerisierbaren, ungesaettigten verbindungen.
ATA901987A (de) Vorrichtung zur erzeugung von gas aus festen brennstoffen
DE3766500D1 (de) Verfahren zur dehalogenierung von halogenierten kohlenwasserstoffen.
DE69314024D1 (de) NEUE GABAa-REZEPTORSUBTYPEN UND VERFAHREN ZUM SCREENING VON ARZNEIMITTELVERBINDUNGEN UNTER VERWENDUNG VON GABAa-REZEPTORSUBTYPEN BINDENDE IMIDAZOCHINOXALINE UND PYRROLOPYRIMIDINE
DE3851925T2 (de) Alkylaminalkoxyphenyl-Derivate, Verfahren zur Verwendung und sie enthaltende Zusammensetzungen.
DE3485319D1 (de) Rekombinante dns, diese rekombinante dns enthaltende bakterien, und verfahren zur herstellung von l-threonin oder l-isoleucin unter verwendung dieser bakterien.
NO854710L (no) Fremgangsmåte for kontroll og styring av injeksjonssonens utstrekning ved jetinjisering av herdbart bindemiddel i jordarter, samt anordning for gjennomføring av fremgangsmåten.
ATE312175T1 (de) Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
DE59001452D1 (de) Verfahren zur optimierung der verbrennung von kraftstoffen bei minimaler co-emission und vorrichtung zur durchfuehrung des verfahrens.
ATA38684A (de) Verfahren zum reinigen von rauchgas aus einer ofenanlage, insbesondere fuer grobkeramische produkte, und ofenanlage fuer dieses verfahren
DE3851493D1 (de) Methode und anlage zur erzeugung von lichtstrahlung aus freiem positronium.
ATE153997T1 (de) Entfärbung von alkylierten diarylaminen
AT375954B (de) Verfahren zur herstellung von selbstvernetzenden, kathodisch abscheidbaren etl-bindemitteln auf basis modifizierter phenol-novolake
DE3768433D1 (de) Durch protonierung mit saeure wasserverduennbare bindemittel.
DK439086A (da) Fremgangsmaader til anvendelse af cellelinier, der mangler humane klasseii histokompatibilitetsantigener
ATA240288A (de) Verfahren zur herstellung von kathodisch abscheidbaren, selbstvernetzenden lackbindemittelnund deren verwendung
DE58900079D1 (de) Verfahren zur verringerung des abbrands von graphitelektroden.
ATE5252T1 (de) 4-benzyloxy-alpha-trichlormethyl-benzylamine, ein verfahren zu ihrer herstellung, sie enthaltende schaedlingsbekaempfungsmittel, ihre herstellung und verwendung.
ATE132476T1 (de) Verfahren zur herstellung von polymergebundenen explosivkörpern

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DANA-FARBER CANCER INSTITUTE, INC., BOSTON, MA, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee